Live
- Vote for Mahayuti means people are with PM, says HM Shah in Maharashtra
- Neeraj Chopra to commence one month off-season training in South Africa later this month
- Grand Celebrations of CM Revanth Reddy’s Birthday
- Telangana Government Forms Cabinet Sub-Committee to Address Employee Issues
- Kishan Reddy Launches Kethineni Digitals: A New Era in the Digital Sector
- Chief Minister Chandrababu Praises Eluru Police for Seizing Stolen Vehicles
- Chief Minister Revanth Reddy Launches 'Moosi Revitalization Sankalp Yatra'
- SBI posts 28 pc net profit growth at Rs 18,331 crore in July-Sep quarter
- Somireddy Chandramohan Reddy announces settlement platform for Tribals in Sarvepalli Constituency
- Vivo X200 Series Global Launch Teased: What to Expect from Vivo's Latest Flagships
Lupin launches generic version of Brovana in the US
Lupin launches generic version of Brovana in the US
Global pharma major, Lupin Limited has announced the launch of the authorised generic version of Brovana (arformoterol tartrate) Inhalation Solution 15 mcg/2 mL, unit-dose vials, of Sunovion Pharmaceuticals Inc, in the United States.
Global pharma major, Lupin Limited has announced the launch of the authorised generic version of Brovana (arformoterol tartrate) Inhalation Solution 15 mcg/2 mL, unit-dose vials, of Sunovion Pharmaceuticals Inc, in the United States.
The drug is used for the maintenance treatment of broncho constriction in patients with chronic obstructive pulmonary disease.
Lupin in a regulatory filing said, "Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL, is indicated for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is for use by nebulization only."
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6 per cent of its revenue in research and development in FY21.
